AIM
KDNY

Alambic Investment Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Alambic Investment Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,140
Closed -$29K – 207
2020
Q1 		$29K Sell
2,140
-540
-20% -$6.38K 0.07% 174
2019
Q4 		$16K Sell
2,680
-5,940
-69% -$32.3K 0.01% 279
2019
Q3 		$46K Buy
8,620
+540
+7% +$3.58K 0.03% 285
2019
Q2 		$62K Buy
+8,080
New +$123K 0.04% 281

Other funds holding KDNY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Alambic Investment Management's KDNY Position: Q2 2020 in Review

Alambic Investment Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2020, closing a stake of 2,140 shares — an estimated $29K sold.

Alambic Investment Management first reported a position in KDNY in Q2 2019 and held it in 4 quarters. The position peaked at $62K in Q2 2019. 90 funds tracked by Wall St. Rank hold KDNY as of Q2 2020.

  • Alambic Investment Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Alambic Investment Management sold 2,140 Chinook Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $29K.
  • Alambic Investment Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2019 and held it in 4 quarters.
  • Alambic Investment Management's Chinook Therapeutics, Inc. Common Stock position peaked at $62K in Q2 2019.
  • 90 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Alambic Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.